Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | C5 | P01031 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CDC42 | P60953 | 1/20 | 0.39 |
| ▸ | RAC1 | P63000 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008369 | 0.82 | PTGS2 (0.49) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL12570797 | 0.79 | CYP3A4 (0.60) | AKR1C2MEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL5122373 | 0.74 | ACHE (0.61) | PTGS2AKR1C3AKR1C2PTGS1KMT2A | |
| SCHEMBL14032691 | 0.74 | ACHE (0.61) | PTGS2AKR1C3AKR1C2PTGS1KMT2A | |
| SCHEMBL490776 | 0.74 | ACHE (0.61) | PTGS2AKR1C3AKR1C2PTGS1KMT2A | |
| Hydrochloric Acid SCHEMBL3225395 | 0.72 | ACHE (0.59) | PTGS2AKR1C3AKR1C2PTGS1KMT2A | |
| SCHEMBL2367665 | 0.70 | ALDH1A1 (0.57) | PTGS2AKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL3315336 | 0.70 | AKR1C3 (0.56) | PTGS2AKR1C3AKR1C2PTGS1CYP3A4 | |
| SCHEMBL16865533 | 0.68 | AKR1C3 (0.62) | PTGS2AKR1C3AKR1C2PTGS1ACHE | |
| SCHEMBL3677141 | 0.68 | AKR1C3 (0.62) | PTGS2AKR1C3AKR1C2PTGS1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164828-B1 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7960567-B2 | Compounds and methods useful for treating asthma and allergic inflammation | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2164828-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | Amgen Inc. (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008137027-A2 | COMPOUNDS AS CRTH2 AND/OR PGD2 RECEPTORS MODULATORS AND THEIR USE FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312270-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION | CCL11, LTC4S, TSLP | PTGS2 59/4885AKR1C3 283/4885AKR1C2 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.